Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy With Concurrent Nelfinavir and Immunotherapy in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma

NCT03050060 is registered in ClinicalTrials.gov with University of Washington as lead sponsor.

NCT NCT03050060
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03050060 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ImmunoRad: Stratified Phase II Trial of Image Guided Hypofractionated Radiotherapy With Concurrent Nelfinavir and Immunotherapy in Advanced Melanoma, Lung Cancer, and Renal Cell Carcinoma
Lead sponsor
University of Washington
Phase
Phase 2
Overall status
Terminated
Start date
June 9, 2017
Completion date
July 12, 2020
Enrollment
21 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic kidney carcinoma, recurrent lung non-small cell carcinoma, stage iv cutaneous melanoma ajcc v6 and v7, stage iv lung non-small cell cancer ajcc v7, stage iv renal cell cancer ajcc v7